Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives $7.00 Consensus PT from Brokerages

Adaptive Biotechnologies Co. (NASDAQ:ADPT) has received a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.00.

Several research firms have weighed in on ADPT. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. increased their price target on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. JTC Employer Solutions Trustee Ltd purchased a new position in Adaptive Biotechnologies during the third quarter valued at $26,000. Manchester Capital Management LLC purchased a new position in Adaptive Biotechnologies during the first quarter valued at $32,000. Rothschild Investment LLC purchased a new position in Adaptive Biotechnologies during the second quarter valued at $36,000. MQS Management LLC purchased a new position in Adaptive Biotechnologies during the second quarter valued at $36,000. Finally, Pinnacle Wealth Planning Services Inc. purchased a new position in Adaptive Biotechnologies during the first quarter valued at $46,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Stock Up 0.9 %

Shares of Adaptive Biotechnologies stock opened at $4.68 on Wednesday. Adaptive Biotechnologies has a twelve month low of $2.28 and a twelve month high of $5.80. The company has a market cap of $689.68 million, a price-to-earnings ratio of -3.14 and a beta of 1.44. The company’s 50 day moving average is $4.69 and its 200 day moving average is $3.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. Adaptive Biotechnologies had a negative net margin of 126.49% and a negative return on equity of 60.99%. The business had revenue of $43.19 million for the quarter, compared to the consensus estimate of $38.63 million. During the same period last year, the firm earned ($0.33) earnings per share. The company’s quarterly revenue was down 11.7% on a year-over-year basis. Sell-side analysts expect that Adaptive Biotechnologies will post -1.19 EPS for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.